Estrogen receptor alpha-Identification by a modeling approach of a potential polyproline II recognizing domain within the AF-2 region of the receptor that would play a role of prime importance in its mechanism of action

Journal of Steroid Biochemistry and Molecular Biology

Volumn 104, Issue 1-2, 2007, Pages 1-10

  Jacquot, Yves ^a   Gallo, Dominique ^b   Leclercq, Guy ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Coactivator recruitment; Estrogen receptor; Polyproline; PPII recognizing domain

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; POLYPROLINE 2; PROLINE; UNCLASSIFIED DRUG;

ARTICLE; MOLECULAR INTERACTION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; SEQUENCE ALIGNMENT;

EID: 33947194001     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.10.008     Document Type: Article

References (55)

1. Ball L.J., Kühne R., Schneider-Mergener J., and Oschkinat H. Recognition of proline-rich motifs by protein-protein interaction domains. Angew. Chem. 44 (2005) 2852-2869
2. Li S.S.C. Specificity and versatility of SH3 and other proline recognition domains: structural basis and implications for cellular signal transduction. Biochem. J. 390 (2005) 641-653
3. Bochicchio B., and Tamburro A.M. Polyproline II structure in proteins: identification by chiroptical spectroscopies, stability, and functions. Chirality 14 (2002) 782-792
4. Björnström L., and Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Mol. Endocrinol. 19 (2005) 833-842
5. Lopez G.N., Webb P., Shinsako J.H., Baxter J.D., Greene G.L., and Kushner P.J. Titration by estrogen receptor activation function-2 targets that are downstream from coactivators. Mol. Endocrinol. 13 (1999) 897-909
6. Pike A.C.W., Brzozowski A.M., and Hubbard R.E. A structural biologist's view of the receptor. J. Steroid Biochem. Mol. Biol. 74 (2000) 261-268
7. Stenoien D.L., Nye A.C., Mancini M.G., Patel K., Dutertre M., O'Malley B.W., Smith C.L., Belmont A.S., and Mancini M.A. Ligand-mediated assembly and real-time cellular dynamics of estrogen receptor α-coactivator complexes in living cells. Mol. Cell Biol. 21 (2001) 4404-4412
8. Driggers P.H., and Segars J.H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signalling. Trends Endocrinol. Metab. 13 (2002) 422-427
9. Kong E.H., Pike A.C.W., and Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem. Soc. Trans. 31 (2003) 56-60
10. Zhou D., Quach K.M., Yang C., Lee S.Y., Pohajdak B., and Chen S. PNRC: A proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (steroidogenic factor 1) and ERRα1 (estrogen related receptor α-1). Mol. Endocrinol. 14 (2000) 986-998
11. Zhou D., Chen B., Ye J.-J., and Chen S. A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction. Oncogene 23 (2004) 5394-5404
12. Zhou D., and Chen S. PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3 binding motif. Nucleic Acids Res. 29 (2001) 3939-3948
13. Yang Z., Barnes C.J., and Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin. Cancer Res. 10 (2004) 3621-3628
14. Simon J.A., and Schreiber S.L. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem. Biol. 2 (1995) 53-60
15. Bar-Sagi D. The Sos (son of sevenless) protein. TEM 5 (1994) 165-168
16. Macias M.J., Wiesner S., and Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. FEBS Lett. 513 (2002) 30-37
17. 13C chemical shifts. J. Mol. Biol. 267 (1997) 933-952
18. Kohda D., Terasawa H., Ichikawa S., Ogura K., Hatanaka H., Mandiyan V., Ullrich A., Schlessinger J., and Inagaki F. Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2. Structure 2 (1994) 1029-1040
19. Larson S.M., and Davidson A.R. The identification of conserved interactions within the SH3 domain by alignment and sequence structures. Protein Sci. 9 (2000) 2170-2180
20. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16 (1988) 10881-10890
21. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
22. Shiau A.K., Barstad D., Loria P.-M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
23. Wärnmark A., Treuter E., Gustafsson J.-A., Hubbard R.E., Brzozowski A.M., and Pike A.C.W.J. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor α. J. Biol. Chem. 277 (2002) 21862-21868
24. Kong E.H., Heldring N., Gustafsson J.-A., Treuter E., Hubbard R.E., and Pike A.C.W. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3593-3598
25. Borchert T.V., Mathieu M., Zeelen J.P., Courtneidge S.A., and Wierenga R.K. The crystal structure of human CskSH3: structural diversity near the RT-Src and n-Src loop. FEBS Lett. 341 (1994) 79-85
26. Dalgarno D.C., Botfield M.C., and Rickles R.J. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers 43 (1997) 383-400
27. Rodriguez A.L., Tamrazi A., Collins M.L., and Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor α coactivator binding. J. Med. Chem. 47 (2004) 600-611
28. Bourdoncle A., Labesse G., Margueron R., Castet A., Cavaillès V., and Royer C.A. The nuclear receptor coactivator PGC-1α exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1. J. Mol. Biol. 347 (2005) 921-924
29. Liu H., Park W.-C., Bentrem D.J., McKian K.P., De Los Reyes A., Loweth J.A., MacGregor Schafer J., Zapf J.W., and Jordan V.C. Structure-function relationships of the raloxifene-estrogen receptor-α complex for regulating transforming growth factor-α expression in breast cancer cells. J. Biol. Chem. 277 (2002) 9189-9198
30. Kong E.H., Pike A.C.W., and Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem. Soc. Trans. 31 (2003) 56-59
31. Ghose R., Shekhtman M.J., Ji Goger H., and Cowburn D. A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat. Struct. Biol. 8 (2001) 998-1004
32. Barnett P., Bottger G., Klein A.T.J., Tabak H.F., and Distel B. The peroxisomal membrane protein Pex13p shows a novel mode of SH3 interaction. EMBO J. 19 (2000) 6382-6391
33. Douangamath A., Filipp F.V., Klein A.T.J., Barnett P., Zou P., Voorn-Brouwer T., Vega M.C., Mayans O.M., Sattler M., Distel B., and Wilmanns M. Topography for independent binding of α-helical and PPII helical ligands to a peroxisomal SH3 domain. Mol. Cell 10 (2002) 1007-1017
34. phox, Grb2 and Pex13p. EMBO J. 21 (2002) 4268-4276
35. Adzhubei A.A., and Sternberg M.J. Left-handed polyproline II helices commonly occur in globular proteins. J. Mol. Biol. 229 (1993) 472-493
36. Mayer B.J. SH3 domains: complexity in moderation. J. Cell Sci. 114 (1993) 1253-1263
37. Wu X., Knudsen B., Feller S.M., Zheng J., Sali A., Cowburn D., and Hanafusa H. Crystal structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation. Structure 3 (1995) 215-226
38. Liu Q., Berry D., Nash P., Pawson T., McGlade C.J., and Li S.S. Structural basis for specific binding of the Gads SH3 domain to an RxxK motif-containing SLP-76 peptide: a novel mode of peptide recognition. Mol. Cell. 11 (2003) 471-481
39. Posern G., Zheng J., Knudsen B.S., Kardinal C., Müller K.B., Voss J., Shishido T., Cowburn D., Cheng G., Wang B., Kruh G.D., Burrell S.K., Jacobson C.A., Lenz D.M., Zamborelli T.J., Adermann K., Hanafusa H., and Feller S.M. Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, Sos and C3G. Oncogene 16 (1998) 1903-1912
40. Kaneko T., Kumasaka T., Ganbe T., Sato T., Miyazawwa K., Kitamura N., and Tanaka N. Structural insight into modest binding of a non-PXXP ligand to the signal transducing adaptor molecule-2 Src homology 3 domain. J. Biol. Chem. 279 (2004) 48162-48168
41. Jia C.Y.H., Nie J., Wu C., Li C., and Li S.S.C. Novel Src homology 3 domain binding motifs identified from proteomic screen of a Pro-rich region. Mol. Cell. Prot. 4 (2005) 1155-1166
42. ++/calmodulin. J. Biol. Chem. 64 (2005) 13097-13104
43. Cui Y., Zhang M., Pestell R., Curran E.M., Welshons W.V., and Fuqua S.A. Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 64 (2004) 9199-9208
44. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., Lisanti M.P., Katzenellenbogen B.S., Kato S., Hopp T., Fuqua S.A.W., Lopez G.N., Kushner P.J., and Pestell R.G. Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276 (2001) 18375-18383
45. Sentis S., Le Romancer M., Bianchin C., Rostan M.-C., and Corbo L. SUMOylation of the estrogen receptor α hinge region regulates its transcriptional activity. Mol. Endocrinol. 19 (2005) 2671-2684
46. Michalides R., Griekspoor A., Balkenende A., Verwoerd D., Janssen L., Jalink K., Floore A., Velds A., van't Veer L., and Neefjed J. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 5 (2004) 597-605
47. Lee H., and Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38 mediated receptor phosphorylation. Mol. Cell. Biol. 22 (2002) 5835-5845
48. Wang R.-A., Mazumdar A., Vadlamudi R.K., and Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-α and promotes hyperplasia in mammary epithelium. EMBO J. 21 (2002) 5437-5447
49. Pierrat B., Heery D.M., Chambon P., and Losson R. A highly conserved region in the hormone-binding domain of the human estrogen receptor functions as an efficient transactivation domain in yeast. Gene 143 (1994) 193-200
50. Yudt M.R., Vorojeikina D.V., Zhong L., Skafar D.F., Sasson S., Gasiewicz T.A., and Notides A.C. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding and transactivation. Biochemistry 38 (1999) 14146-14156
51. Arnold S.F., and Notides A.C. An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7475-7479
52. Arnold S.F., Melamed M., Vorojeikina D.P., Notides A.C., and Sasson S. Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol. Endocrinol. 11 (1997) 48-53
53. Zhong L., and Skafar D.F. Mutations of tyrosine 537 in the human estrogen receptor-α selectively alter the receptor's affinity for estradiol and the kinetics of the interaction. Biochemistry 41 (2002) 4209-4217
54. van Hoorn W.P. Identification of a second binding site in the estrogen receptor. J. Med. Chem. 45 (2002) 584-589
55. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., and Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 8 (2001) 269-280